Aduro's CRS-207 meets in Phase II for pancreatic cancer

Aduro BioTech Inc. (Berkeley, Calif.) stopped early a Phase II trial evaluating CRS-207 plus GVAX Pancreas cancer vaccine and cyclophosphamide to treat pancreatic cancer after the combination met the primary endpoint of improving overall survival (OS) vs. GVAX Pancreas and cyclophosphamide alone (6 vs. 3.4 months, p=0.0114). The open-label, U.S. trial enrolled 90 patients with metastatic pancreatic ductal adenocarcinoma (PDA) who received or refused one or more prior chemotherapy regimen. Data are slated to be presented at the American Society of Clinical Oncology meeting in June. Aduro declined to disclose next steps for CRS-207, a live attenuated strain of Listeria monocytogenes that expresses human mesothelin. ...